To reduce side effects, several strategies have been developed to specifically target cytokines to tumor cells or to the tumor niche, such as “immunocytokines”, composed of a cytokine, e.g. IFN, fused to a monoclonal antibody that recognizes a cell surface marker on the target cell [4, 6]. The gene discussed is IFNA1; the disease is neoplasm.